FG-2216 is primarily investigated for its ability to activate hypoxia-inducible factor (HIF) pathways by inhibiting prolyl hydroxylase enzymes. This mechanism makes it a candidate for stimulating erythropoiesis, or red blood cell production, particularly in patients with chronic kidney disease suffering from anemia. Unlike traditional erythropoiesis-stimulating agents that require injection, FG-2216 was explored as an oral alternative, offering potential convenience and improved patient compliance. Its action under normoxic conditions mimics the body’s natural response to low oxygen, promoting the production of endogenous erythropoietin. Although development faced challenges due to toxicity concerns in preclinical studies, FG-2216 contributed valuable insights into the therapeutic potential of HIF stabilizers, paving the way for safer successors in anemia treatment.